PERCEPTIC RAISES $12M FOR AI DRUG DEVELOPMENT

Perceptic positions itself as a comprehensive AI solution for drug development, with backing from top pharmaceutical companies already using the platform. The funding comes as the biotech sector increasingly adopts machine learning to accelerate research and reduce development timelines. The startup's founding team brings significant enterprise software experience from Palantir, where they developed tools for intelligence and data analysis. This expertise translates directly to pharma's complex data challenges around molecular analysis, clinical trials, and drug candidate identification. Ackel's investment signals confidence in AI-driven drug development as a category. The $12 million seed round will likely fund platform expansion and talent recruitment. Perceptic joins a growing cohort of AI-first biotech platforms targeting the $2 trillion pharmaceutical industry. The company operates in a competitive space alongside initiatives from established pharma giants and well-funded startups, though its enterprise pedigree differentiates its approach to regulatory-grade AI systems.